Acerus Pharmaceuticals (ASP-T) Stock Predictions - Stockchase
WATCH LIST
6
Acerus Pharmaceuticals (ASP-T)

ON STOCKCHASE SINCE May 2012

A pharmaceutical company developing medications for male hypogonadism, female sexual dysfunction and various respiratory disorders.

Formerly Trimel Pharmaceuticals (Sept 2015)

Consumer Products

Acerus Pharmaceuticals

ASP-T

4 watching          
Join the Discussion

Acerus Pharmaceuticals (ASP-T) SAVE Apr, 24, 2019, 11:49 am

0.15 0 (0%)

What the experts are saying about ASP-T



  • All
  • Filtered
Signal Opinion Expert
HOLD

Good company. In some interesting spaces in terms of hormonal stuff. They are on the search for a Viagra for women. The numbers into 2016 are looking pretty good. He wants to see one or 2 more quarters, but if they keep doing things the way they are, it is a name he would be interested in. Wouldn’t be surprised if he ends up owning it in 2016.

Consumer Products
0 0 0 0 0
0 comments

Good company. In some interesting spaces in terms of hormonal stuff. They are on the search for a Viagra for women. The numbers into 2016 are looking pretty good. He wants to see one or 2 more quarters, but if they keep doing things the way they are, it is a name he would be interested in. Wouldn’t be surprised if he ends up owning it in 2016.

Consumer Products
0 0 0 0 0
0 comments
Jason Donville

President , Donville Kent Asset ...

Price Price
$0.405
Owned Owned
No

COMMENT

Working on an application of testosterone. In the current method you have to be extremely careful using it. This is a nasal application. If successful, it will be beneficial. There seems to be a debate of testosterone supplementing for men, which seems to have died down a little. There will be a reasonable opportunity to get the results over the next 6 months. Lost $0.27 last year, which is improving to a loss of $0.11 this year. If they are successful, the stock could be quite significant. Very speculative.

Consumer Products
0 0 0 0 0
0 comments

Working on an application of testosterone. In the current method you have to be extremely careful using it. This is a nasal application. If successful, it will be beneficial. There seems to be a debate of testosterone supplementing for men, which seems to have died down a little. There will be a reasonable opportunity to get the results over the next 6 months. Lost $0.27 last year, which is improving to a loss of $0.11 this year. If they are successful, the stock could be quite significant. Very speculative.

Consumer Products
0 0 0 0 0
0 comments
Robert McWhirte

President, Selective Asset Mana...

Price Price
$0.470
Owned Owned
Unknown

DON'T BUY
Acerus Pharmaceuticals(ASP-T) 

September 6, 2013

(Market Call Minute.) Wouldn’t own this. Too risky and there are a lot of financing issues. High risk.

Consumer Products
0 0 0 0 0
0 comments

(Market Call Minute.) Wouldn’t own this. Too risky and there are a lot of financing issues. High risk.

Consumer Products
0 0 0 0 0
0 comments
Fabrice Taylor

Publisher, The President's Club...

Price Price
$0.830
Owned Owned
No

COMMENT

Have an ingenious nasal application system. Still waiting for the next stages of approval, particularly on the application for men. Application for women is behind that.

Consumer Products
0 0 0 0 0
0 comments

Have an ingenious nasal application system. Still waiting for the next stages of approval, particularly on the application for men. Application for women is behind that.

Consumer Products
0 0 0 0 0
0 comments
Michael Smedley

Exec VP & , Morgan Meighan & Ass...

Price Price
$1.940
Owned Owned
Yes

HOLD

In the drug delivery systems business. Good management. Into phase 3. Part of the problem recently is that one of the big investors has been selling, which has spooked some people.

Consumer Products
0 0 0 0 0
0 comments

In the drug delivery systems business. Good management. Into phase 3. Part of the problem recently is that one of the big investors has been selling, which has spooked some people.

Consumer Products
0 0 0 0 0
0 comments
Michael Smedley

Exec VP & , Morgan Meighan & Ass...

Price Price
$1.610
Owned Owned
Unknown

WATCH
New drug delivery for more testosterone. Got a lot of attention because they are working on the female Viagra. It is a concept stock because they are in trials. If it works out it could be a huge win. But there are no revenue or earnings at this point so there is a lot of ability for downside. A licensing deal would be the catalyst.
Consumer Products
0 0 0 0 0
0 comments
New drug delivery for more testosterone. Got a lot of attention because they are working on the female Viagra. It is a concept stock because they are in trials. If it works out it could be a huge win. But there are no revenue or earnings at this point so there is a lot of ability for downside. A licensing deal would be the catalyst.
Consumer Products
0 0 0 0 0
0 comments
Peter Imhof

Vice Presi, AGF Investments Inc...

Price Price
$3.190
Owned Owned
Unknown

Showing 1 to 6 of 6 entries
Successfully Saved Company
Successfully Saved Company
3+
JOIN THE DISCUSSION
3 comments in the last 7 days